Search Results

You are looking at 181 - 190 of 535 items for :

  • "pathology" x
  • Refine by Access: All x
Clear All
Full access

Richard B. Hostetter, Min Yan, Houman Vaghefi, Kenneth Pennington, and Gary Cornette

higher total doses (60–66 Gy in 30–33 fractions). The advantage of adjuvant therapy is that the final pathology is clearly established. 3 Figure 6 Spindle tumor cells in bundle and fascicles (hematoxylin-eosin stain, original magnification x100

Full access

Badar M. Mian

biopsies in a population-based screening study: the impact of borderline lesions . Cancer 1999 ; 85 : 145 – 152 . 35 Orozco R O'Dowd G Kunnel B . Observations on pathology trends in 62,537 prostate biopsies obtained from urology private

Full access

Brady L. Stein, Susan O’Brien, Peter Greenberg, and Ruben A. Mesa

Pathology . J Mol Diagn 2006 ; 8 : 412 – 419 . 12. Maxson JE Gotlib J Pollyea DA . Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML . N Engl J Med 2013 ; 368 : 1781 – 1790 . 13. Piazza R Valletta S

Full access

Gregory P. Kalemkerian

only medical and radiation oncology, but also thoracic surgery, pathology, and diagnostic radiology. Another substantial improvement in the NCCN Guidelines for SCLC (and many others) has been the inclusion of “Principles of” sections that provide

Full access

Brian Vicuna and Al B. Benson III

: 65 – 69 . 15. Morris E Maughan NJ Forman D Quirke P . Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? – The need for high quality pathology . Gut 2007 ; 56 : 1419 – 1425 . 16. Soreide K Janssen EA

Full access

Lori J. Goldstein, Bonnie J. Miller, Nancy Nicotera, and Delinda Pendleton

hand-offs that occur during the intake and registration processes; obtaining patient materials (pathology tissue, radiology films) with complete interpretation in advance of the patient’s first visit; and wherever possible, performance of studies in

Full access

Henry Soo-Min Park

radiation oncology, medical oncology, pathology, radiology, and internal medicine subspecialties, potentially influencing overall survival in a manner that is independent of the institution’s case volume of the particular surgery of interest. Even if we

Full access

Louis Burt Nabors, Jana Portnow, Mario Ammirati, Joachim Baehring, Henry Brem, Nicholas Butowski, Robert A. Fenstermaker, Peter Forsyth, Jona Hattangadi-Gluth, Matthias Holdhoff, Steven Howard, Larry Junck, Thomas Kaley, Priya Kumthekar, Jay S. Loeffler, Paul L. Moots, Maciej M. Mrugala, Seema Nagpal, Manjari Pandey, Ian Parney, Katherine Peters, Vinay K. Puduvalli, John Ragsdale III, Jason Rockhill, Lisa Rogers, Chad Rusthoven, Nicole Shonka, Dennis C. Shrieve, Allen K. Sills Jr, Lode J. Swinnen, Christina Tsien, Stephanie Weiss, Patrick Yung Wen, Nicole Willmarth, Mary Anne Bergman, and Anita Engh

Pathology” (see BRAIN-F, pages 1334 and 1335) to provide background and recommendations for histologic characterization and molecular testing for gliomas. This article also describes data from clinical trials with available molecular information that have

Full access

Kilian E. Salerno

Neoadjuvant Treatment Following neoadjuvant chemotherapy, indications for RT should be guided by maximal disease stage from either prechemotherapy tumor characteristics at diagnosis or postchemotherapy pathology results. Patients with residual nodal disease

Full access

Frank Balis, Daniel M. Green, Clarke Anderson, Shelly Cook, Jasreman Dhillon, Kenneth Gow, Susan Hiniker, Rama Jasty-Rao, Chi Lin, Harold Lovvorn III, Iain MacEwan, Julian Martinez-Agosto, Elizabeth Mullen, Erin S. Murphy, Mark Ranalli, Daniel Rhee, Denise Rokitka, Elisabeth (Lisa) Tracy, Tamara Vern-Gross, Michael F. Walsh, Amy Walz, Jonathan Wickiser, Matthew Zapala, Ryan A. Berardi, and Miranda Hughes

kidney, hydronephrosis, metanephric tumors (ie, adenoma, stromal tumor, adenofibroma), multicystic kidney disease, polycystic kidney disease, renal hemorrhage, and renal vein thrombosis. Pathology To avoid potential tumor spread from malignant